Pills to think about in allergic rhinitis children during COVID‐19 era

Brindisi, Giulia; Vittori, Valentina De; Castro, Giovanna De; Duse, Marzia; Zicari, Anna Maria

doi:10.1111/apa.15462

Cited by 22 publications

(21 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nosulya et al found that the expression of VCAM-1 in the lung tissues of anaphylactic shock rats increased with the progression of anaphylactic shock, indicating that VCAM-1 is a key molecular involved in allergic reactions (17). The findings of the present study indicated that the level of VCAM-1 in the observation group was significantly higher than that in the control group, which is consistent with the results reported in the previously published studies (18).…”

Section: Discussionsupporting

confidence: 92%

Expression and clinical significance of VCAM-1, IL-6, and IL-17A in patients with allergic rhinitis

Gao

Zhang³

et al. 2021

Ann Palliat Med

View full text Add to dashboard Cite

Background: Allergic rhinitis is a chronic inflammatory disease with a high incidence, affecting the quality of life of patients. The aim of the present study was to explore the expression and clinical significance of vascular endothelial cell adhesion molecule-1 (VCAM-1), interleukin (IL)-6, and IL-17A in patients with allergic rhinitis.Methods: A total of 180 patients with allergic rhinitis, who were admitted to our hospital from March 2017 to March 2020, were enrolled as the observation group. Patients were further divided into 3 subgroups according to the degree of severity of allergic rhinitis as follows: the mild group (n=66), the moderate group (n=60), and the severe group (n=54). During the same period, 188 people without allergic rhinitis, who underwent physical examination in our hospital, were enrolled as the control group. VCAM-1, IL-6, and IL-17A levels were compared between these groups, and the correlation between the 3 levels and allergic rhinitis was analyzed.Results: VCAM-1, IL-6, and IL-17A levels in the observation group were significantly higher than those in the control group, and the difference was statistically significant (P<0.05). Comparison results of VCAM-1, IL-6 and IL-17A levels among the 3 groups were as follows: mild group < moderate group < severe group, and the differences between the three groups were significant (P<0.05). Pearson linear correlation showed that serum levels of VCAM-1, IL-6 and IL-17A were positively correlated with ARIA (P<0.05). Parent history of allergic rhinitis, living environment pollution, abnormally elevated VCAM-1, abnormally elevated IL-6 and abnormally elevated IL-6 were the related risk factors for inducing allergic rhinitis (P<0.05).Conclusions: VCAM-1, IL-6, and IL-17A play important roles in allergic rhinitis, and the concentration will increase with disease progression. Clinical testing of VCAM-1, IL-6, IL-17A should be increased to improve the diagnostic rate for early allergic rhinitis and to prevent disease progression.

show abstract

Section: Discussionsupporting

confidence: 92%

Expression and clinical significance of VCAM-1, IL-6, and IL-17A in patients with allergic rhinitis

Gao

Zhang³

et al. 2021

Ann Palliat Med

View full text Add to dashboard Cite

show abstract

“…We compliment the discussion by Brindisi et al 1 It has been recently reported that elderly asthmatic patients receiving montelukast had a significant reduction in the acquisition of COVID-19 compared to those without receiving montelukast. 3 Whether montelukast can be effective to decrease the risk of acquisition or to prevent severe outcomes from COVID-19 among paediatric patients needs to be confirmed in clinical trials.…”

Section: Montelukast In Children With Allergic Rhinitis Amid Covid-19supporting

confidence: 88%

“…We compliment the discussion by Brindisi et al 1 on the management of allergic rhinitis in children amid novel coronavirus disease 2019 (COVID‐19) pandemic. Brindisi et al 1 presented a well‐reasoned discussion on the use of intranasal corticosteroids and allergen immunotherapy in children with allergic rhinitis amid COVID‐19 pandemic where they recommend continuation of the former while withholding of the latter upon risk‐benefit assessment.…”

mentioning

confidence: 52%

Montelukast in children with allergic rhinitis amid COVID‐19 pandemic

Kow

Hasan

2020

Acta Paediatrica

View full text Add to dashboard Cite

“…Allergic patients with an acute phase of COVID-19 infection should continue standard therapy, except biological drugs and allergen immunotherapy (AIT). They should use on-demand therapy during exacerbations [ 23 , 24 ]. According to the improvement of symptoms in our patients, the use of on-demand therapy (salbutamol for asthma and nasal steroids/antihistamine for rhinitis) and basal therapy was markedly lower during the lockdown compared to the same period in 2019.…”

Section: Discussionmentioning

confidence: 99%

Updates on Children with Allergic Rhinitis and Asthma during the COVID-19 Outbreak

Brindisi

Vittori

Nola

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

Background: During the lockdown period caused by the SARS-CoV-2 pandemic, we monitored via online survey the trend of allergic symptoms and the therapeutic compliance in patients followed at our center. Material and methods: In June 2020, we selected children followed at the Allergy and Immunology Service of Umberto I Hospital, aged between 6 and 16 years old, diagnosed with asthma and/or rhinitis and sensitized to grass pollen or dust mite. We sent an email with 12 multiple-choice questions investigating several areas: type of disease and sensitization, recurrence of symptoms, medication use during lockdown compared to the same period of the previous year. Results: The results of 82 questionnaires showed that 17.8% of patients suffered from asthma, 24.4% from rhinitis, and 57.8% from both. Within the group of asthmatic children, most of them presented an improvement of their symptoms. Likewise, with regard to allergic rhinitis, most of them reported better clinical conditions. Regarding treatment, we observed a global decrease in the use of on-demand therapies (salbutamol, nasal corticosteroid, and antihistamine) for both pathologies. In addition, there was a reduction in the use of basal therapy for asthma and rhinitis from 2019 (23.3%) to 2020 (15.5%). Conclusions: Our data show a general trend of clinical improvement and a reduction in the use of on-demand and basal therapy in allergic children during the lockdown.

show abstract

Pills to think about in allergic rhinitis children during COVID‐19 era

Cited by 22 publications

References 6 publications

Expression and clinical significance of VCAM-1, IL-6, and IL-17A in patients with allergic rhinitis

Expression and clinical significance of VCAM-1, IL-6, and IL-17A in patients with allergic rhinitis

Montelukast in children with allergic rhinitis amid COVID‐19 pandemic

Updates on Children with Allergic Rhinitis and Asthma during the COVID-19 Outbreak

Contact Info

Product

Resources

About